anti- braf v600e mouse monoclonal antibody clone ve1  (Spring Bioscience)

Journal: Brain Pathology

Article Title: Integrated genotype–phenotype analysis of long‐term epilepsy‐associated ganglioglioma

doi: 10.1111/bpa.13011

Figure Lengend Snippet: Summary of the clinico‐pathologic features and molecular alterations in the patient cohort

Article Snippet: The following primary antibodies were used: anti‐BRAF V600E (Spring Bioscience, USA, monoclonal, clone VE1, 1:50), anti‐CD34 (Zymed, USA, monoclonal, clone QBEnd 10, 1:50), anti‐neurofilament protein (NF; OriGene, USA, monoclonal, clone 2F11, 1:200), anti‐ neuronal nuclear antigen (NeuN; Chemicon, USA, monoclonal, 1:4000), anti‐ glial fibrillary acidic protein (GFAP; OriGene, USA, monoclonal, clone UMAB129, 1:200), and anti‐Ki67 (MIB‐1; OriGene, USA, monoclonal, clone UMAB107, 1:200).

Techniques:

Journal: Brain Pathology

Article Title: Integrated genotype–phenotype analysis of long‐term epilepsy‐associated ganglioglioma

doi: 10.1111/bpa.13011

Figure Lengend Snippet: Clinical and histopathology features of 30 patients with GG

Article Snippet: The following primary antibodies were used: anti‐BRAF V600E (Spring Bioscience, USA, monoclonal, clone VE1, 1:50), anti‐CD34 (Zymed, USA, monoclonal, clone QBEnd 10, 1:50), anti‐neurofilament protein (NF; OriGene, USA, monoclonal, clone 2F11, 1:200), anti‐ neuronal nuclear antigen (NeuN; Chemicon, USA, monoclonal, 1:4000), anti‐ glial fibrillary acidic protein (GFAP; OriGene, USA, monoclonal, clone UMAB129, 1:200), and anti‐Ki67 (MIB‐1; OriGene, USA, monoclonal, clone UMAB107, 1:200).

Techniques: Histopathology

Journal: Brain Pathology

Article Title: Integrated genotype–phenotype analysis of long‐term epilepsy‐associated ganglioglioma

doi: 10.1111/bpa.13011

Figure Lengend Snippet: Histopathology findings in BRAF p.V600E mutated GG with seizure recurrence. (A–D) A GG with a characteristic glial‐neuronal phenotype and hemosiderin deposition (A‐HE), the strongly positive CD34 staining (B), positive BRAF V600E (C) immunoreactivity and low ki‐67 proliferation index (D) in the lesion (GG‐16). (E–H) A GG with a characteristic glial‐neuronal phenotype (E‐HE), the fine positive CD34 immunoreactivity (F), enriched neurofilament (G) and low ki‐67 proliferation index (H) (GG‐17). (I–L) A case with intermingled GG and PXA components (I‐HE), increased reticular fiber deposition in PXA region (J), the strongly positive BRAF V600E (K) immunoreactivity and low ki‐67 proliferation index (L) in the tumor lesion (GG‐18). (M–P) A case with both GG component (M‐HE, shown as the asterisk marked area in the upper right corner) and PXA component (O‐HE, shown as a triangle marked area in the upper right corner) was conducted the genomic profiling respectively. The CD34 staining was diffusely positive in GG component (N), while displayed a fine pattern in PXA component (P) (GG‐19)

Article Snippet: The following primary antibodies were used: anti‐BRAF V600E (Spring Bioscience, USA, monoclonal, clone VE1, 1:50), anti‐CD34 (Zymed, USA, monoclonal, clone QBEnd 10, 1:50), anti‐neurofilament protein (NF; OriGene, USA, monoclonal, clone 2F11, 1:200), anti‐ neuronal nuclear antigen (NeuN; Chemicon, USA, monoclonal, 1:4000), anti‐ glial fibrillary acidic protein (GFAP; OriGene, USA, monoclonal, clone UMAB129, 1:200), and anti‐Ki67 (MIB‐1; OriGene, USA, monoclonal, clone UMAB107, 1:200).

Techniques: Histopathology, Staining

Journal: Brain Pathology

Article Title: Integrated genotype–phenotype analysis of long‐term epilepsy‐associated ganglioglioma

doi: 10.1111/bpa.13011

Figure Lengend Snippet: Histopathology findings in genetically positive, none‐ BRAF p.V600E mutated GG. (A–D) A case with both, GG (A‐HE, shown as the asterisk marked area in the upper right corner) and DNT components (C‐HE, shown as a triangle marked area in the upper right corner) (GG‐22) were detected both harboring IRS2 CNG in two components, respectively. The CD34 staining was diffusely positive in GG component (B). Floating neuron is interspersed in a mucoid matrix surrounded by oligodendrocyte‐like cells (C). And scanty positive CD34 immunoreactivity was observed in DNT component (D). (E–H) A GG with several neurons scattered in glial cells (E‐HE), the positive CD34 immunoreactivity (F), negative BRAF V600E staining (G) and low ki‐67 proliferation index (H). The tumor harbored KRAS p.Q22R and KRAS p.G13R mutations (GG‐23)

Article Snippet: The following primary antibodies were used: anti‐BRAF V600E (Spring Bioscience, USA, monoclonal, clone VE1, 1:50), anti‐CD34 (Zymed, USA, monoclonal, clone QBEnd 10, 1:50), anti‐neurofilament protein (NF; OriGene, USA, monoclonal, clone 2F11, 1:200), anti‐ neuronal nuclear antigen (NeuN; Chemicon, USA, monoclonal, 1:4000), anti‐ glial fibrillary acidic protein (GFAP; OriGene, USA, monoclonal, clone UMAB129, 1:200), and anti‐Ki67 (MIB‐1; OriGene, USA, monoclonal, clone UMAB107, 1:200).

Techniques: Histopathology, Staining

Journal: Brain Pathology

Article Title: Integrated genotype–phenotype analysis of long‐term epilepsy‐associated ganglioglioma

doi: 10.1111/bpa.13011

Figure Lengend Snippet: Histopathology findings in BRAF p.V600E mutated GG with postsurgical seizure control. (A–D) Magnetic resonance imaging image of a case with local signal abnormalities in the right anterior temporal lobe (A). Macroscopically, well‐delineated brown lesion involving cortex and white matter was observed (B, white arrows). Microscopically, dysplastic neurons presented the binucleated form (C, black arrow), and CD34 immunostaining showed diffuse pattern along the lesion (B, D) (GG‐01). (E–H) A GG with a characteristic glial‐neuronal phenotype (E‐HE), showed strong CD34 immunoreactivity with subpial spread (F), neuronal components (G) and positive BRAF V600E immunostaining (H) (GG‐02). (I–L) A case with clustering of dysmorphic ganglion cells (I‐HE) and astrocyte‐element (K), had CD34‐immunoreactive cell cluster (J) and positive BRAF V600E immunoreactivity (L) (GG‐05)

Article Snippet: The following primary antibodies were used: anti‐BRAF V600E (Spring Bioscience, USA, monoclonal, clone VE1, 1:50), anti‐CD34 (Zymed, USA, monoclonal, clone QBEnd 10, 1:50), anti‐neurofilament protein (NF; OriGene, USA, monoclonal, clone 2F11, 1:200), anti‐ neuronal nuclear antigen (NeuN; Chemicon, USA, monoclonal, 1:4000), anti‐ glial fibrillary acidic protein (GFAP; OriGene, USA, monoclonal, clone UMAB129, 1:200), and anti‐Ki67 (MIB‐1; OriGene, USA, monoclonal, clone UMAB107, 1:200).

Techniques: Histopathology, Control, Magnetic Resonance Imaging, Immunostaining

Journal: Brain Pathology

Article Title: Integrated genotype–phenotype analysis of long‐term epilepsy‐associated ganglioglioma

doi: 10.1111/bpa.13011

Figure Lengend Snippet: Univariate and multivariate Cox analyses of 30 GG for Sex, CD34 expression, glial component, Ki‐67, extent of resection and BRAF V600E

Article Snippet: The following primary antibodies were used: anti‐BRAF V600E (Spring Bioscience, USA, monoclonal, clone VE1, 1:50), anti‐CD34 (Zymed, USA, monoclonal, clone QBEnd 10, 1:50), anti‐neurofilament protein (NF; OriGene, USA, monoclonal, clone 2F11, 1:200), anti‐ neuronal nuclear antigen (NeuN; Chemicon, USA, monoclonal, 1:4000), anti‐ glial fibrillary acidic protein (GFAP; OriGene, USA, monoclonal, clone UMAB129, 1:200), and anti‐Ki67 (MIB‐1; OriGene, USA, monoclonal, clone UMAB107, 1:200).

Techniques: Expressing

Journal: BMJ Case Reports

Article Title: BRAF V600E-mutated combined large cell neuroendocrine carcinoma and adenocarcinoma responding to targeted therapy

doi: 10.1136/bcr-2021-243295

Figure Lengend Snippet: (A) The cerebral tumour is a mixture of adenocarcinoma-like cells that form and proliferate small ducts, and atypical cells with abundant acidophilic cytoplasm and distinct nucleoli. (B) Synaptophysin is diffusely positive in all regions. (C) Immunostaining of BRAF V600E with cerebellar tumours stain both adenocarcinoma and large cell neuroendocrine carcinoma. Both cells showing adenocarcinoma morphology and LCNEC cells stained for synaptophysin are stained with BRAF V600E antibody.

Article Snippet: Immunostaining of BRAF V600E (anti- BRAF V600E rabbit monoclonal antibody clones: RM8, RevMAb Biosciences) with cerebellar tumours tested positive in both adenocarcinoma and LCNEC ( ).

Techniques: Immunostaining, Staining

Journal: Annals of Surgical Oncology

Article Title: Quantitative and Spatial Analysis of CD8+/PD-1 Tumor-Infiltrating Lymphocytes as a Predictive Biomarker for Clinical Response of Melanoma In-Transit Metastases to Topical Immunotherapy

doi: 10.1245/s10434-020-08713-1

Figure Lengend Snippet: Lymphocyte biomarkers and distribution by BRAF mutation status

Article Snippet: For BRAF V600E IHC, Pleasanton, CA Spring Bioscience mouse anti-human BRAF V600E monoclonal antibody (Clone VE1) was used at a dilution of 1:200 run on a routine long program.

Techniques: Mutagenesis

Journal: Annals of Surgical Oncology

Article Title: Quantitative and Spatial Analysis of CD8+/PD-1 Tumor-Infiltrating Lymphocytes as a Predictive Biomarker for Clinical Response of Melanoma In-Transit Metastases to Topical Immunotherapy

doi: 10.1245/s10434-020-08713-1

Figure Lengend Snippet: Clinical response to DPCP correlated with OS by biomarker status

Article Snippet: For BRAF V600E IHC, Pleasanton, CA Spring Bioscience mouse anti-human BRAF V600E monoclonal antibody (Clone VE1) was used at a dilution of 1:200 run on a routine long program.

Techniques: Biomarker Assay